North America Anti diabetic Biosimilars Market: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)and Geography

Purchase Option

$ 3000
$ 4400
$ 4600
$ 6900

North America Anti diabetic Biosimilars Market size was valued at USD x billion in 2021 and is expected to reach USD x billion by 2028, at a CAGR of x% during the forecast period 2022-2028. Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.

North America Anti Diabetic Biosimilars Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

North America Anti diabetic Biosimilars Market Dynamics

Drivers: Increase in the prevalence of diabetic patients. Patent expiries block buster drugs and promising product pipeline. Rise in R&D activities for the innovation of Insulin biosimilars Restraints: High cost of R&D activities. Stringent regulatory policies. Complexity in development of biosimilars

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

North America Anti Diabetic Biosimilars Market Segmentation

By Drug Class
  • Insulin
  • Biguanides
  • Sulfonyl Ureas
  • Thiazolidinediones
  • Di Peptidyl Peptidase (DPP)-IV Inhibitors
  • ?-glucosidase Inhibitos
  • GLP-1 Agonists
  • Others
By Disease Type
  • Type-I Diabetes
  • Type-II Diabetes
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly & Co. (U.S.)
  • Sanofi-aventis U.S. LLC (U.S.)
  • Samsung Bioepis (Samsung BioLogics) (South Korea)
  • Mylan N.V. (U.S.)
  • Wockhardt (India)